* Veracyte Inc VCYT.OQ VCYT.O is expected to show a rise
in
quarterly revenue when it reports results on February 22.
* The South San Francisco California-based company is
expected to
report a 11.3% increase in revenue to $74.911 million from
$67.34 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Veracyte Inc is for
a
loss of 15 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Veracyte
Inc is
$33, above its last closing price of $25.46.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.24 -0.25 -0.12 Beat 51.7
Jun. 30 2022 -0.22 -0.22 -0.13 Beat 40.5
Mar. 31 2022 -0.24 -0.24 -0.20 Beat 15.9
Dec. 31 2021 -0.18 -0.16 -0.15 Beat 6.9
Sep. -0.17 -0.16 -0.20 Missed -21.2
30 2021
Jun. 30 2021 -0.25 -0.25 -0.13 Beat 48.4
Mar. 31 2021 -0.12 -0.12 -0.11 Beat 8.3
Dec. 31 2020 -0.10 -0.11 -0.14 Missed -30.2
This summary was machine generated February 21 at 00:21 GMT.
All figures in US dollars unless otherwise stated